1. Home
  2. ETJ vs PCRX Comparison

ETJ vs PCRX Comparison

Compare ETJ & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETJ
  • PCRX
  • Stock Information
  • Founded
  • ETJ 2007
  • PCRX 2006
  • Country
  • ETJ United States
  • PCRX United States
  • Employees
  • ETJ N/A
  • PCRX N/A
  • Industry
  • ETJ Finance Companies
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ETJ Finance
  • PCRX Health Care
  • Exchange
  • ETJ Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • ETJ 578.8M
  • PCRX 1.2B
  • IPO Year
  • ETJ N/A
  • PCRX 2011
  • Fundamental
  • Price
  • ETJ $8.99
  • PCRX $22.90
  • Analyst Decision
  • ETJ
  • PCRX Buy
  • Analyst Count
  • ETJ 0
  • PCRX 8
  • Target Price
  • ETJ N/A
  • PCRX $28.38
  • AVG Volume (30 Days)
  • ETJ 175.6K
  • PCRX 525.8K
  • Earning Date
  • ETJ 01-01-0001
  • PCRX 07-29-2025
  • Dividend Yield
  • ETJ 8.30%
  • PCRX N/A
  • EPS Growth
  • ETJ N/A
  • PCRX N/A
  • EPS
  • ETJ N/A
  • PCRX N/A
  • Revenue
  • ETJ N/A
  • PCRX $702,772,000.00
  • Revenue This Year
  • ETJ N/A
  • PCRX $7.92
  • Revenue Next Year
  • ETJ N/A
  • PCRX $11.02
  • P/E Ratio
  • ETJ N/A
  • PCRX N/A
  • Revenue Growth
  • ETJ N/A
  • PCRX 3.08
  • 52 Week Low
  • ETJ $7.20
  • PCRX $11.16
  • 52 Week High
  • ETJ $8.47
  • PCRX $27.64
  • Technical
  • Relative Strength Index (RSI)
  • ETJ 54.61
  • PCRX 35.82
  • Support Level
  • ETJ $8.60
  • PCRX $22.82
  • Resistance Level
  • ETJ $9.02
  • PCRX $23.83
  • Average True Range (ATR)
  • ETJ 0.07
  • PCRX 0.74
  • MACD
  • ETJ -0.00
  • PCRX -0.02
  • Stochastic Oscillator
  • ETJ 63.89
  • PCRX 6.22

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: